Roche Highlights Cancer Treatment Advances at ESMO 2025

Overview

Roche will present over 30 abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place from October 17-21 in Berlin, Germany. These presentations cover advancements in treatments for more than 10 cancer types, including breast, lung, gastrointestinal, and genitourinary cancers.

Key Studies

Significant studies include the Giredestrant phase III evERA Breast Cancer study, which is the first positive head-to-head phase III trial of a selective estrogen receptor degrader regimen versus standard care in ER-positive, HER2-negative breast cancer. The study met both co-primary endpoints, showing improvements in progression-free survival.

The Tecentriq IMvigor011 trial is the first global phase III study using a ctDNA-guided approach for post-surgery treatment in muscle-invasive bladder cancer. Results indicate significant improvements in disease-free and overall survival for patients with detectable ctDNA treated with Tecentriq.

Alecensa's final overall survival data from the ALEX study and updated results from the ALINA study reinforce its role as a standard treatment for ALK-positive non-small cell lung cancer.

Presentation Schedule

Key presentations will include late-breaking oral abstracts and sessions at the ESMO Congress. The Giredestrant study will be presented on October 18, Tecentriq results will be part of the Presidential Symposium on October 20, and Alecensa data will be shared on October 17 and 20.